The IDKmonitor® Adalimumab Total ADA ELISA is intended for the determination of human antibodies against TNFα blocker adalimumab (e.g. HUMIRA®) in the presence of adalimumab in EDTA plasma and serum.

Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, or rheumatoid arthritis are often treated with anti-TNFα antibodies which directly target underlying inflammatory processes. The clinical efficacy of an anti-TNFα therapy correlates with the trough level of the therapeutic antibody, the drug level just before the next application of the anti-TNFα antibody. Several factors influence the trough level, among them dosage and frequency of anti-TNFα blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation of anti-drug antibodies, ADA). It is thought that ADA functionally neutralizes the therapeutic antibodies or induces their rapid elimination.

Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFα antibody application. This IDKmonitor® Adalimumab Total ADA ELISA allows for a reliable determination of ADA even in the presence of adalimumab; therefore, it is ideal for therapy monitoring when a measurable adalimumab concentration is expected. In combination with the drug level determination, the IDKmonitor® Adalimumab Total ADA ELISA can help physicians monitor and optimize therapy early on.